191 results about "Calcitonin" patented technology

The present application discloses compounds of formula I for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present application is directed to compounds of formula I which modulate calcitonin receptor and / or amylin receptor activity and can be useful in the treatment of bone, metabolic, cardiovascular, neurodegenerative and other disorders.

A compound, as shown in Formula I, is a multi-heterocyclic compound. It has been verified that the compound provided by this invention integrates a novel compound targeting the calcitonin gene-related peptide (CGRP) based on ephedrine. Upon contact with the skin, due to photoactivated cell biological function regulation and the blocking effect of the multi-heterocyclic compound I structure on serotonin receptors, it achieves therapeutic effects on cutaneous vascular malformations and telangiectasia, improves the effectiveness of phototherapy in improving chronic cutaneous vascular diseases, and promotes skin wound healing.

The invention discloses an abdominal aortic aneurysm progress prediction method and system based on cross-modal knowledge distillation. The method comprises the following steps: collecting blood of a target object; the method comprises the following steps: detecting the concentration of blood protein fingerprint markers of blood of a target object, wherein the blood protein fingerprint markers comprise matrix metalloproteinase-12, calcitonin-related polypeptide-alpha, uromodulin, nerve injury induction protein-1, glycosylated hemoglobin A1c and fibroblast growth factor-9; carrying out abdominal aortic aneurysm risk calculation by calling Student-net of cross-modal knowledge distillation based on the blood protein fingerprint marker concentration; wherein the input of the Teaser-net of the cross-modal knowledge distillation comprises a CTA image feature and a pathological section feature, and a category probability vector output by the Student-net is aligned with a category probability vector output by the Teaser-net; and outputting the risk level of the abdominal aortic aneurysm and the probability of occurrence / progress / rupture of the abdominal aortic aneurysm in the preset year. And the development of the aortic aneurysm disease is accurately predicted.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The invention belongs to the technical field of in-vitro diagnosis and rapid detection, and relates to an interleukin 6 and procalcitonin joint detection kit, a preparation method and a detection method, the interleukin 6 and procalcitonin joint detection kit comprises a Ra1 reagent, a Ra2 reagent, an Rb1 reagent, an Rb2 reagent and a substrate solution; the Ra1 reagent is an interleukin 6 antibody magnetic bead labeling solution, and is prepared from a biotin labeled interleukin 6 first antibody solution and a streptavidin magnetic bead solution; the Ra2 reagent is a procalcitonin antibody magnetic bead labeling solution, and is prepared from a biotin labeled procalcitonin first antibody solution and a streptavidin magnetic bead solution; the Rb1 reagent is prepared from an alkaline phosphatase labeled interleukin 6 second antibody solution; the Rb2 reagent is prepared from a second procalcitonin antibody solution labeled by horse radish peroxidase; the substrate solution comprises a first substrate solution and a second substrate solution. The detection sensitivity can be improved, the detection time is shortened, the detection efficiency is improved, and the operation is simple.

Methods, systems, and computer storage media may be used to detect and differentiate bacterial and viral infections. Cellular population parameters such as the monocyte distribution width (MDW) can be acquired for an individual. Clinical measurements such as a complete blood count (CBC), a measure of procalcitonin (PCT) or a measure of C-reactive protein (CRP)can be obtained for an individual. A trained model can be used to compute an output value from the parameters. The output value can be compared to a threshold value to determine a probability associated with a bacterial or viral infection. A report can be generated from the probability and sent to the appropriate party.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

Room-temperature stable dosage forms for oral delivery of calcitonin are disclosed herein. Dosage forms for oral delivery of calcitonin with low water content are also disclosed herein. Further disclosed herein are methods for producing such room-temperature stable dosage forms and low-water content dosage forms. Methods of treatment comprising the administration of such room-temperature stable dosage forms and low-water content dosage forms are also disclosed herein.

The inventors discovered that calcitonin gene-related peptide (CGRP) inhibitors reduce pain caused by bone fracture without impeding healing of the fracture. Accordingly, disclosed herein are methods for treating pain in a subject that has sustained a bone fracture, and the methods comprise administering a therapeutically effective amount of a CGRP inhibitor to the subject.

The invention relates to a sepsis detection system which evaluates the sepsis risk of a patient in real time by integrating clinical signs, various physiological parameters, laboratory detection data and biomarkers and utilizing an intelligent algorithm. The system comprises a data acquisition module, a data transmission module, a data processing module, a user display module and an alarm module. The data acquisition module monitors physiological parameters such as consciousness, body temperature, heart rate, respiratory rate, finger pulse oxygen saturation, invasive blood pressure, urine volume and skin piebald in real time, and biomarker data such as leukocyte count, neutrophile granulocyte, neutrophile granulocyte number, C-reactive protein, procalcitonin and interleukin-6 are obtained through blood detection. And the data processing module performs sepsis risk assessment by integrating the biomarkers and the physiological parameters in combination with a machine learning model, and outputs a risk level. The user display module displays the evaluation result in real time and provides treatment suggestions, and the alarm module triggers an alarm under the high-risk condition to ensure timely intervention.

The present invention provides a stable calcitonin calibrator and a preparation method thereof, belonging to the technical field of calibrator preparation. The calibrator comprises the following components: a buffer, a salt substance, a sugar substance, a polyol substance, a preservative, a protein substance, a composite protective agent and calcitonin; the composite protective agent is obtained by mixing sodium caseinate, sodium hydroxypropyl methylcellulose and sodium carboxymethyl cellulose in a mass ratio of 2:1:1. The calcitonin calibrator of the present invention has a validity period of up to 36 months, can be stable for 1 year under the condition of ‑20°C after re-dissolution, can be stable for 3 months under the condition of 2‑8°C after re-dissolution, and can be stable for 1 month under the condition of room temperature after re-dissolution, providing a stable and good-performance calibrator for calcitonin diagnostic reagents.

The present invention relates to a process for preparing the compound of Formula I in the form of a base or a salt thereof, and its use as an intermediate for the preparation of calcitonin gene- related peptide (CGRP) receptor antagonist active pharmaceutical ingredients, in particular zavegepant, where the compound of Formula I is the following: (I)

Nausea and vomiting are unpleasant events caused by a variety of triggering factors. Wherein medicines often cause nausea and vomiting. An anti-tumor chemotherapeutic agent is one of the most emetic drugs, and often causes chemotherapy-induced nausea and vomiting (CINV). The latter seriously impairs the therapeutic effect and the quality of life of the patient. It is of great interest in determining agents capable of preventing and combating drug-induced nausea and vomiting, including CINV. A calcitonin gene-related peptide (CGRP) is a neuropeptide having various effects in a human body. However, neuropeptide effects in the brain are still to be clarified. CGRP receptor antagonists (named as gezepam) have been recently approved for use in the treatment of migraine. The use of gezepams for the direct treatment of nausea and vomiting, including CINV, is described.

The application discloses a kind of light illumination methods for laying hens in later egg production stage.The method comprises: in the breeding process of laying hens in later egg production stage, using light source to emit blue light illumination or blue light and white light illumination to irradiate laying hens, so that the illumination can improve eggshell quality.The method of the application can up-regulate the expression of CaBP-D28k gene in eggshell gland of laying hens in later production stage, improve the ability of eggshell calcium deposition, regulate the secretion of parathyroid hormone PTH, calcitonin CT and other hormones, maintain the balance of blood calcium and blood phosphorus, and effectively improve the strength, thickness and weight of eggshell, so as to improve the eggshell quality of eggs produced by laying hens.The application can improve the calcium and phosphorus absorption capacity of laying hens, maintain the balance of calcium and phosphorus metabolism, and has low energy consumption, green energy-saving and environment-friendly advantages.

Interoception is the mechanism by which an individual is informed about the status of its own body. When interoception becomes dysfunctional, it turns into a deleterious event for the health status of an individual. The use of calcitonin gene-related peptide (CGRP) receptor antagonists (gepants) for the treatment and 70 prevention of interoception disorders is described.

The invention features methods for preventing or treating CGRP associated disorders such as vasomotor symptoms and / or headaches (e.g., migraine, cluster headache, and tension headache) by administering an anti-CGRP antagonist antibody. Compositions for use in the disclosed methods are also provided. Antagonist antibody G1 and antibodies derived from G1 directed to CGRP are also described.

The present disclosure related to the field of medicine. More particularly, the disclosure is in the field of treatment of diabetes, obesity, and / or dyslipidemia. The disclosure relates to compounds that agonize both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, so can be used to treat diabetes, obesity and / or dyslipidemia. The present disclosure also includes pharmaceutical compositions containing such compounds and therapeutic uses of such compounds and compositions.

The present invention provides a recombinant protein of monkey procalcitonin, a monoclonal antibody thereof, and a preparation method and application thereof. The amino acid sequence of the recombinant protein of monkey procalcitonin is shown as SEQ ID No.1, and the nucleotide sequence encoding the recombinant protein is shown as SEQ ID No.2. By optimizing the antigen peptide sequence and expression vector, the high-efficiency and soluble expression of monkey procalcitonin in Escherichia coli is achieved. A murine monoclonal antibody specifically binding to monkey procalcitonin is screened based on the recombinant protein of monkey procalcitonin, and a pair of monoclonal antibodies that can be paired is screened using the above murine monoclonal antibody. Further, a double-antibody sandwich immuno-ELISA detection method or kit for the recombinant protein of monkey procalcitonin is constructed based on the pair of monoclonal antibody combinations, which has high detection sensitivity and can be well applied to the detection of monkey serum.

The invention relates to a calcitonin luminescence detection kit and a detection method and application thereof. Specifically, the invention provides the high-sensitivity calcitonin luminescence detection kit, the high-sensitivity calcitonin luminescence detection kit comprises a first reagent and a second reagent, and the first reagent comprises magnetic beads connected with first protein; the second reagent comprises alkaline phosphatase connected with the second protein. The kit improves the detection accuracy and the sample coincidence rate.

The present invention belongs to the field of clinical diagnosis. In particular, the present invention relates to assessing the severity of a subject suspected of infection or having an infection by determining the level of procalcitonin (hereinafter: PCT) (SEQ ID No: 1) and / or proadrenomedullin (hereinafter: proADM) (SEQ ID No: 3) or a partial peptide or fragment thereof, in particular mid-region proadrenomedullin (MR-proADM) (SEQ ID No: 2) in a patient sample, wherein the subject may have physiological signs of infection or increased risk factors, in particular from an infectious disease, and the present invention relates to its workflow. In addition, the present invention relates to assessments related to infection, such as exclusion / determination of patients and stratification, risk assessment, in particular to avoid re-hospitalization and hospital and post-discharge deaths.

The present disclosure provides compounds for modulating calcitonin receptor and / or amylin receptor activity, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating a calcitonin receptor and / or amylin receptor associated disease or disorder.

The application provides a photochemical chemiluminescence detection reagent and a preparation method thereof, and a procalcitonin detection method. The photochemical chemiluminescence detection reagent comprises acceptor microspheres and donor microspheres; wherein the acceptor microspheres are carboxyl-modified acceptor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody; and the donor microspheres are carboxyl-modified donor microspheres, and the carboxyl is activated by sulfo-NHS / EDC and coupled with a procalcitonin antibody. The photochemical chemiluminescence detection reagent has higher stability in various environments, can more accurately combine with target molecules, realizes more efficient detection and recognition, and enables the microspheres to more accurately capture and fix the target molecules, so as to perform subsequent luminescence reaction. The detection method has high sensitivity and a wide range, can be used as a detection reagent for diagnosing and identifying infectious diseases of individuals, and has application value.

To provide compounds that stimulate both the calcitonin and amylin receptors and can lower food intake, body weight, glucose and / or triglycerides, making them suitable for treating diabetes, obesity and / or dyslipidemia.SOLUTION: The present disclosure provides compounds with specific sequences, serving as dual amylin and calcitonin receptor agonists. The present disclosure also includes pharmaceutical compositions containing the compounds and therapeutic uses of the compounds and compositions.SELECTED DRAWING: None

The present invention discloses an anti-procalcitonin antibody or a reagent and kit for detecting procalcitonin, relating to the field of antibodies. The anti-procalcitonin antibody disclosed in the present invention comprises a heavy chain complementary determining region and a light chain complementary determining region. The antibody provides an important source of raw materials for the detection of procalcitonin and has good affinity or activity.

Disclosed herein is a wearable drug delivery device including a container filled at least partially with a drug including at least one of a PCSK9 (Proprotein Convertase Subtilisin / Kexin Type 9) specific antibody, a granulocyte colony-stimulating factor (G-CSF), a sclerostin antibody, or a calcitonin gene-related peptide (CGRP) antibody. The wearable drug delivery device may include a needle and an insertion mechanism configured to insert the needle into a patient. A fluid pathway connector may define a sterile fluid flowpath between the container and the insertion mechanism. Optionally, a cannula initially disposed about the needle may be included. The cannula may be retained in the patient at an injection site created by the needle after the needle is withdrawn from the patient. Methods of assembly and operation are also provided.